Chang-ki Y. Min
Experienced in Hemolytic Anemia

Chang-ki Y. Min

Seoul St. Mary's Hospital, 
Seoul, KR 
Experienced in Hemolytic Anemia
Seoul St. Mary's Hospital, 
Seoul, KR 
OverviewLocationsClinical Research

Overview

Chang-ki Min practices in Seoul, Republic of Korea. Min is rated as an Experienced expert by MediFind in the treatment of Hemolytic Anemia. Their top areas of expertise are Multiple Myeloma, Plasmacytoma, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Splenectomy.

Their clinical research consists of co-authoring 342 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Hemolytic Anemia.

Locations

Seoul St. Mary's Hospital, Seoul, Republic of Korea
Other Locations
Seoul St. Mary's Hospital, 222 Banpodaero, 06591, Seocho, Republic of Korea
Jeonju, Republic of Korea
Republic of Korea
Incheon St. Mary's Hospital, Incheon, Republic of Korea
Pohang, Republic of Korea
St. Vincent Hospital College Of Medicine, Suwon, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-labeled, Multicenter Phase II Study
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-labeled, Multicenter Phase II Study
Enrollment Status: Completed
Publish Date: February 20, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

342 Total Publications

Real-world treatment outcome of defibrotide for treatment of severe hepatic VOD/SOS after hematopoietic cell transplantation.
Real-world treatment outcome of defibrotide for treatment of severe hepatic VOD/SOS after hematopoietic cell transplantation.
Journal: Transplantation and cellular therapy
Published: June 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Min's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile